FDA accepts Axsome's NDA resubmission for AXS-07 migraine treatment; PDUFA date Jan 31, 2025

Axsome Therapeutics, Inc.

FDA acknowledged Class 2 resubmission of NDA for AXS-07 for acute migraine treatment.
PDUFA goal date set for January 31, 2025.
AXS-07 is a novel oral drug candidate for acute migraine.

item 8.01 item 9.01

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-103098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.